Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

~34 mi. (Rogers, Arkansas, +606 more cities)

Highlands Oncology Group

CD274 Amplification

Angiosarcoma, +26 more conditions

ipilimumab, +1 more drug

immunotherapy

A Safety, Pharmacokinetic, Pharmacodynamic and Anti-Tumor Study of PF-06873600 as a Single Agent and in Combination With Endocrine Therapy

~34 mi. (Rogers, Arkansas, +32 more cities)

Highlands Oncology Group

ER Negative, +4 more biomarkers

Breast Carcinoma, +3 more conditions

hormone therapy, +1 more drug

hormone therapy, +1 more type

Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.

~34 mi. (Rogers, Arkansas, +23 more cities)

Highlands Oncology Group

PD-L1 Expression (Expression >= 1%)

Head and Neck Squamous Cell Carcinoma, +3 more conditions

PF-07257876

immunotherapy

Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian

~34 mi. (Rogers, Arkansas, +27 more cities)

Highlands Oncology Group

Fallopian Tube Clear Cell Adenocarcinoma, +8 more conditions

afuresertib, +1 more drug

chemotherapy, +1 more type

A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

~34 mi. (Rogers, Arkansas, +15 more cities)

Highlands Oncology

Malignant Solid Tumor, +1 more condition

alrizomadlin, +1 more drug

immunotherapy, +1 more type

Study of PF-07265807 in Participants With Metastatic Solid Tumors.

~34 mi. (Rogers, Arkansas, +10 more cities)

Highlands Oncology Group

MET Exon 14 Skipping, +8 more biomarkers

Adenocarcinoma of the Gastroesophageal Junction, +5 more conditions

axitinib, +2 more drugs

immunotherapy, +1 more type

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

~34 mi. (Rogers, Arkansas, +7 more cities)

Highlands Oncology

BCR-ABL1 Fusion, +1 more biomarker

Acute Lymphoblastic Leukemia, +1 more condition

HQP1351

targeted therapy

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

~43 mi. (Springdale, Arkansas, +266 more cities)

Research Site

ERBB2 Amplification, +1 more biomarker

Breast Carcinoma

fam-trastuzumab deruxtecan, +2 more drugs

targeted therapy

A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease.

~43 mi. (Springdale, Arkansas, +230 more cities)

Research Site

ER Positive, +1 more biomarker

Breast Carcinoma

camizestrant, +3 more drugs

hormone therapy, +1 more type

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

~43 mi. (Springdale, Arkansas, +292 more cities)

Research Site

ER Positive, +2 more biomarkers

Breast Carcinoma

fam-trastuzumab deruxtecan

targeted therapy

Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

~43 mi. (Springdale, Arkansas, +206 more cities)

Highlands Oncology Group - Springdale

Non-Squamous Non-Small Cell Lung Carcinoma

nivolumab, +1 more drug

immunotherapy, +1 more type

Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

~43 mi. (Springdale, Arkansas, +189 more cities)

Highlands Oncology Group /ID# 221826

del(11)(q10), +27 more biomarkers

Myelofibrosis Transformation in Essential Thrombocythemia, +2 more conditions

navitoclax, +1 more drug

targeted therapy